FDAapproval95% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (nmus rehab) as Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Anesthesia · Neuromuscular Blockade
- Sub-indication
- Nmus Rehab
Related signal: FDA Grants Approval for Sugammadex Sodium ANDA214319 by Sun Pharma